nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.122	0.141	CbGbCtD
Norethindrone—CYP3A7—Vincristine—muscle cancer	0.122	0.141	CbGbCtD
Norethindrone—ABCB1—Dactinomycin—muscle cancer	0.0969	0.112	CbGbCtD
Norethindrone—CYP3A5—Vincristine—muscle cancer	0.0916	0.106	CbGbCtD
Norethindrone—CYP3A5—Etoposide—muscle cancer	0.084	0.0971	CbGbCtD
Norethindrone—ALB—Methotrexate—muscle cancer	0.069	0.0799	CbGbCtD
Norethindrone—ABCB1—Vincristine—muscle cancer	0.0596	0.069	CbGbCtD
Norethindrone—ABCB1—Etoposide—muscle cancer	0.0547	0.0632	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—muscle cancer	0.0373	0.0431	CbGbCtD
Norethindrone—ABCB1—Methotrexate—muscle cancer	0.0361	0.0418	CbGbCtD
Norethindrone—CYP3A4—Vincristine—muscle cancer	0.0357	0.0413	CbGbCtD
Norethindrone—CYP3A4—Etoposide—muscle cancer	0.0327	0.0379	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—muscle cancer	0.0223	0.0258	CbGbCtD
Norethindrone—Embolism arterial—Doxorubicin—muscle cancer	0.0116	0.0854	CcSEcCtD
Norethindrone—Cerebral thrombosis—Methotrexate—muscle cancer	0.00768	0.0567	CcSEcCtD
Norethindrone—Infertility—Methotrexate—muscle cancer	0.00369	0.0272	CcSEcCtD
Norethindrone—Blindness—Vincristine—muscle cancer	0.00359	0.0264	CcSEcCtD
Norethindrone—Cerebral haemorrhage—Vincristine—muscle cancer	0.00359	0.0264	CcSEcCtD
Norethindrone—Thromboembolic event—Methotrexate—muscle cancer	0.00358	0.0264	CcSEcCtD
Norethindrone—Abdominal cramps—Vincristine—muscle cancer	0.00294	0.0217	CcSEcCtD
Norethindrone—Menorrhagia—Vincristine—muscle cancer	0.00268	0.0198	CcSEcCtD
Norethindrone—Optic neuritis—Etoposide—muscle cancer	0.00261	0.0193	CcSEcCtD
Norethindrone—Erythema nodosum—Doxorubicin—muscle cancer	0.00193	0.0142	CcSEcCtD
Norethindrone—Deep vein thrombosis—Methotrexate—muscle cancer	0.00158	0.0117	CcSEcCtD
Norethindrone—Blindness—Doxorubicin—muscle cancer	0.00151	0.0111	CcSEcCtD
Norethindrone—Embolism—Methotrexate—muscle cancer	0.0015	0.0111	CcSEcCtD
Norethindrone—Pain in extremity—Vincristine—muscle cancer	0.00144	0.0106	CcSEcCtD
Norethindrone—Optic neuritis—Doxorubicin—muscle cancer	0.00136	0.01	CcSEcCtD
Norethindrone—Embolism—Doxorubicin—muscle cancer	0.0013	0.00958	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Etoposide—muscle cancer	0.00121	0.0089	CcSEcCtD
Norethindrone—Thrombosis—Doxorubicin—muscle cancer	0.00118	0.00869	CcSEcCtD
Norethindrone—Photosensitivity reaction—Vincristine—muscle cancer	0.00114	0.00839	CcSEcCtD
Norethindrone—Dermatitis atopic—Doxorubicin—muscle cancer	0.00113	0.00831	CcSEcCtD
Norethindrone—Vaginal haemorrhage—Doxorubicin—muscle cancer	0.00113	0.00831	CcSEcCtD
Norethindrone—Hepatitis—Dactinomycin—muscle cancer	0.00112	0.00823	CcSEcCtD
Norethindrone—Depression—Vincristine—muscle cancer	0.00111	0.00817	CcSEcCtD
Norethindrone—Acute coronary syndrome—Vincristine—muscle cancer	0.00109	0.00807	CcSEcCtD
Norethindrone—Myocardial infarction—Vincristine—muscle cancer	0.00109	0.00803	CcSEcCtD
Norethindrone—Erythema multiforme—Dactinomycin—muscle cancer	0.00105	0.00778	CcSEcCtD
Norethindrone—Alopecia—Dactinomycin—muscle cancer	0.000986	0.00727	CcSEcCtD
Norethindrone—Connective tissue disorder—Vincristine—muscle cancer	0.00098	0.00723	CcSEcCtD
Norethindrone—Neoplasm malignant—Doxorubicin—muscle cancer	0.000977	0.0072	CcSEcCtD
Norethindrone—Pulmonary embolism—Methotrexate—muscle cancer	0.000963	0.00711	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—muscle cancer	0.000956	0.00705	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—muscle cancer	0.000949	0.007	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—muscle cancer	0.000949	0.007	CcSEcCtD
Norethindrone—Acute coronary syndrome—Etoposide—muscle cancer	0.000887	0.00654	CcSEcCtD
Norethindrone—Renal failure—Etoposide—muscle cancer	0.000884	0.00652	CcSEcCtD
Norethindrone—Myocardial infarction—Etoposide—muscle cancer	0.000882	0.0065	CcSEcCtD
Norethindrone—Alopecia—Vincristine—muscle cancer	0.000881	0.0065	CcSEcCtD
Norethindrone—Mental disorder—Vincristine—muscle cancer	0.000873	0.00644	CcSEcCtD
Norethindrone—Hepatobiliary disease—Etoposide—muscle cancer	0.000851	0.00628	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—muscle cancer	0.000834	0.00615	CcSEcCtD
Norethindrone—Thrombophlebitis—Methotrexate—muscle cancer	0.000808	0.00596	CcSEcCtD
Norethindrone—Photosensitivity—Methotrexate—muscle cancer	0.000796	0.00587	CcSEcCtD
Norethindrone—Oedema—Dactinomycin—muscle cancer	0.000793	0.00585	CcSEcCtD
Norethindrone—Erythema multiforme—Etoposide—muscle cancer	0.000764	0.00563	CcSEcCtD
Norethindrone—Convulsion—Vincristine—muscle cancer	0.000752	0.00555	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—muscle cancer	0.000729	0.00538	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Methotrexate—muscle cancer	0.000722	0.00533	CcSEcCtD
Norethindrone—Alopecia—Etoposide—muscle cancer	0.000714	0.00526	CcSEcCtD
Norethindrone—Anaphylactic shock—Vincristine—muscle cancer	0.000708	0.00522	CcSEcCtD
Norethindrone—Oedema—Vincristine—muscle cancer	0.000708	0.00522	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—muscle cancer	0.000699	0.00516	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—muscle cancer	0.00069	0.00509	CcSEcCtD
Norethindrone—Fatigue—Dactinomycin—muscle cancer	0.000683	0.00504	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—muscle cancer	0.000662	0.00489	CcSEcCtD
Norethindrone—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000648	0.00478	CcSEcCtD
Norethindrone—Insomnia—Vincristine—muscle cancer	0.000641	0.00472	CcSEcCtD
Norethindrone—Renal impairment—Doxorubicin—muscle cancer	0.000636	0.00469	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—muscle cancer	0.000632	0.00466	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—muscle cancer	0.000628	0.00463	CcSEcCtD
Norethindrone—Abdominal pain—Dactinomycin—muscle cancer	0.000627	0.00462	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.000626	0.00461	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vincristine—muscle cancer	0.000611	0.00451	CcSEcCtD
Norethindrone—Fatigue—Vincristine—muscle cancer	0.000611	0.0045	CcSEcCtD
Norethindrone—Convulsion—Etoposide—muscle cancer	0.000609	0.00449	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—muscle cancer	0.000605	0.00447	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—muscle cancer	0.000596	0.0044	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—muscle cancer	0.000596	0.0044	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000594	0.00438	CcSEcCtD
Norethindrone—Hypersensitivity—Dactinomycin—muscle cancer	0.000584	0.00431	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vincristine—muscle cancer	0.000579	0.00427	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—muscle cancer	0.000574	0.00423	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—muscle cancer	0.000574	0.00423	CcSEcCtD
Norethindrone—Asthenia—Dactinomycin—muscle cancer	0.000569	0.0042	CcSEcCtD
Norethindrone—Abdominal pain—Vincristine—muscle cancer	0.00056	0.00413	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—muscle cancer	0.000557	0.00411	CcSEcCtD
Norethindrone—Photosensitivity reaction—Methotrexate—muscle cancer	0.000552	0.00407	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—muscle cancer	0.000547	0.00404	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—muscle cancer	0.000539	0.00397	CcSEcCtD
Norethindrone—Depression—Methotrexate—muscle cancer	0.000537	0.00396	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—muscle cancer	0.00053	0.00391	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—muscle cancer	0.000527	0.00389	CcSEcCtD
Norethindrone—Hypersensitivity—Vincristine—muscle cancer	0.000522	0.00385	CcSEcCtD
Norethindrone—Somnolence—Etoposide—muscle cancer	0.00051	0.00376	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—muscle cancer	0.00051	0.00376	CcSEcCtD
Norethindrone—Asthenia—Vincristine—muscle cancer	0.000508	0.00375	CcSEcCtD
Norethindrone—Vomiting—Dactinomycin—muscle cancer	0.000504	0.00372	CcSEcCtD
Norethindrone—Rash—Dactinomycin—muscle cancer	0.0005	0.00369	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—muscle cancer	0.000495	0.00365	CcSEcCtD
Norethindrone—Fatigue—Etoposide—muscle cancer	0.000495	0.00365	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—muscle cancer	0.000486	0.00359	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—muscle cancer	0.000484	0.00357	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—muscle cancer	0.000484	0.00357	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000478	0.00352	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—muscle cancer	0.000476	0.00351	CcSEcCtD
Norethindrone—Nausea—Dactinomycin—muscle cancer	0.000471	0.00347	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—muscle cancer	0.000469	0.00346	CcSEcCtD
Norethindrone—Dizziness—Vincristine—muscle cancer	0.000468	0.00345	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—muscle cancer	0.000467	0.00344	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—muscle cancer	0.000459	0.00338	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—muscle cancer	0.000457	0.00337	CcSEcCtD
Norethindrone—Urticaria—Etoposide—muscle cancer	0.000456	0.00336	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—muscle cancer	0.000454	0.00335	CcSEcCtD
Norethindrone—Vomiting—Vincristine—muscle cancer	0.00045	0.00332	CcSEcCtD
Norethindrone—Rash—Vincristine—muscle cancer	0.000447	0.00329	CcSEcCtD
Norethindrone—Dermatitis—Vincristine—muscle cancer	0.000446	0.00329	CcSEcCtD
Norethindrone—Headache—Vincristine—muscle cancer	0.000444	0.00327	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000441	0.00325	CcSEcCtD
Norethindrone—Immune system disorder—Methotrexate—muscle cancer	0.000437	0.00322	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—muscle cancer	0.000427	0.00315	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—muscle cancer	0.000424	0.00313	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—muscle cancer	0.000423	0.00312	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—muscle cancer	0.000421	0.00311	CcSEcCtD
Norethindrone—Nausea—Vincristine—muscle cancer	0.000421	0.0031	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—muscle cancer	0.000419	0.00309	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—muscle cancer	0.000419	0.00309	CcSEcCtD
Norethindrone—Asthenia—Etoposide—muscle cancer	0.000412	0.00304	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—muscle cancer	0.000412	0.00304	CcSEcCtD
Norethindrone—Pruritus—Etoposide—muscle cancer	0.000406	0.00299	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—muscle cancer	0.000396	0.00292	CcSEcCtD
Norethindrone—Dizziness—Etoposide—muscle cancer	0.000379	0.0028	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—muscle cancer	0.000378	0.00279	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—muscle cancer	0.00037	0.00273	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—muscle cancer	0.000367	0.00271	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—muscle cancer	0.000365	0.00269	CcSEcCtD
Norethindrone—Vomiting—Etoposide—muscle cancer	0.000365	0.00269	CcSEcCtD
Norethindrone—Rash—Etoposide—muscle cancer	0.000362	0.00267	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—muscle cancer	0.000361	0.00267	CcSEcCtD
Norethindrone—Headache—Etoposide—muscle cancer	0.000359	0.00265	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—muscle cancer	0.000359	0.00265	CcSEcCtD
Norethindrone—Tension—Doxorubicin—muscle cancer	0.000358	0.00264	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000356	0.00263	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—muscle cancer	0.000354	0.00261	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—muscle cancer	0.000344	0.00253	CcSEcCtD
Norethindrone—Nausea—Etoposide—muscle cancer	0.000341	0.00251	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—muscle cancer	0.000334	0.00246	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—muscle cancer	0.000316	0.00233	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—muscle cancer	0.000311	0.00229	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000308	0.00227	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—muscle cancer	0.000306	0.00225	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—muscle cancer	0.000302	0.00223	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—muscle cancer	0.000298	0.00219	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—muscle cancer	0.000298	0.00219	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000297	0.00219	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—muscle cancer	0.000296	0.00219	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—muscle cancer	0.000289	0.00213	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—muscle cancer	0.000281	0.00207	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—muscle cancer	0.000273	0.00201	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—muscle cancer	0.000272	0.002	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—muscle cancer	0.000269	0.00199	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—muscle cancer	0.000265	0.00195	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—muscle cancer	0.000262	0.00193	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000257	0.00189	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—muscle cancer	0.000257	0.00189	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—muscle cancer	0.000253	0.00187	CcSEcCtD
Norethindrone—Asthenia—Methotrexate—muscle cancer	0.000247	0.00182	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000243	0.00179	CcSEcCtD
Norethindrone—Pruritus—Methotrexate—muscle cancer	0.000243	0.00179	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—muscle cancer	0.000236	0.00174	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—muscle cancer	0.000235	0.00174	CcSEcCtD
Norethindrone—Dizziness—Methotrexate—muscle cancer	0.000227	0.00168	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—muscle cancer	0.000219	0.00162	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—muscle cancer	0.000218	0.00161	CcSEcCtD
Norethindrone—Rash—Methotrexate—muscle cancer	0.000217	0.0016	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—muscle cancer	0.000216	0.0016	CcSEcCtD
Norethindrone—Headache—Methotrexate—muscle cancer	0.000215	0.00159	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—muscle cancer	0.000213	0.00157	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—muscle cancer	0.000211	0.00155	CcSEcCtD
Norethindrone—Nausea—Methotrexate—muscle cancer	0.000204	0.00151	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—muscle cancer	0.000197	0.00145	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—muscle cancer	0.000189	0.0014	CcSEcCtD
Norethindrone—Rash—Doxorubicin—muscle cancer	0.000188	0.00138	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—muscle cancer	0.000187	0.00138	CcSEcCtD
Norethindrone—Headache—Doxorubicin—muscle cancer	0.000186	0.00138	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—muscle cancer	0.000177	0.0013	CcSEcCtD
